Patents Assigned to Seattle Genetics, Inc.
  • Publication number: 20220298243
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Application
    Filed: April 7, 2022
    Publication date: September 22, 2022
    Applicants: Bristol-Myers Squibb Company, Seattle Genetics, Inc.
    Inventors: Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER
  • Publication number: 20210047404
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Application
    Filed: July 29, 2020
    Publication date: February 18, 2021
    Applicant: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Patent number: 10912842
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: February 9, 2021
    Assignee: Seattle Genetics, Inc.
    Inventors: May Kung Sutherland, Lori Westendorf, Django Sussman
  • Publication number: 20210017213
    Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.
    Type: Application
    Filed: April 16, 2020
    Publication date: January 21, 2021
    Applicant: Seattle Genetics, Inc.
    Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
  • Publication number: 20210008099
    Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.
    Type: Application
    Filed: February 20, 2019
    Publication date: January 14, 2021
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana O. Doronina, Philip Moquist
  • Publication number: 20210011021
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.
    Type: Application
    Filed: February 14, 2020
    Publication date: January 14, 2021
    Applicant: Seattle Genetics, Inc.
    Inventors: Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
  • Publication number: 20210002380
    Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
    Type: Application
    Filed: May 7, 2020
    Publication date: January 7, 2021
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Charlotte McDonagh, Paul Carter
  • Patent number: 10828375
    Abstract: The present invention provides a method for removing cysteine caps from antibodies and re-capping the antibodies with cysteine molecules. The methods include, inter alia, culturing a host cell comprising a protein molecule having at least one capped engineered cysteine residue, and contacting the cell culture with cystine. Dissolved oxygen levels can be manipulated in the cell culture to further enhance the removal and re-capping process.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: November 10, 2020
    Assignee: Seattle Genetics, Inc.
    Inventors: Swapnil Bhargava, Cheng-Wei Aaron Chen, Matthew J. Leith
  • Patent number: 10808039
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: October 20, 2020
    Assignee: Seattle Genetics Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
  • Publication number: 20200306336
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Patent number: 10787514
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: September 29, 2020
    Assignee: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Publication number: 20200297864
    Abstract: Improved processes for the preparation of tubulysin compounds, tubulysin drug linker compounds, and their intermediates are disclosed.
    Type: Application
    Filed: September 7, 2018
    Publication date: September 24, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Kun-Liang Wu, Qingwu Jin, Wendel Doubleday
  • Publication number: 20200289661
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD48 and conjugates thereof.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 17, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Timothy Lewis, Kristine Gordon, Lori Westendorf
  • Publication number: 20200276306
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include mono clonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. In some embodiments, the present invention provides an antibody having a heavy chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 63 and having a light chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 64.
    Type: Application
    Filed: January 14, 2020
    Publication date: September 3, 2020
    Applicant: Seattle Genetics, Inc.
    Inventors: Ana Paula Galvao da Silva, Julie DeSander, Jeffrey Behrens, Darius Ghaderi, Mai Zhang, Kristan Meetze
  • Publication number: 20200247902
    Abstract: Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.
    Type: Application
    Filed: November 17, 2017
    Publication date: August 6, 2020
    Applicant: Seattle Genetics, Inc.
    Inventors: Jillian M. Prendergast, David A. Eavarone, Patricia Rao
  • Patent number: 10722592
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD48 and conjugates thereof.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 28, 2020
    Assignee: Seattle Genetics, Inc.
    Inventors: Timothy Lewis, Kristine Gordon, Lori Westendorf
  • Patent number: 10722549
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: July 28, 2020
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Publication number: 20200230254
    Abstract: This invention relates to treatment of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Specifically, the disclosure provides a method of treating a subject having DLBCL or FL, the method comprising administering to the subject a drug combination consisting essentially of a CD19 antibody drug conjugate (CD19-ADC), and rituximab, cyclophosphamide, doxorubicin, and prednisone (RCHP).
    Type: Application
    Filed: July 21, 2017
    Publication date: July 23, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventor: Ana Kostic
  • Publication number: 20200222553
    Abstract: The present invention provides improved processes for the preparation of drug-linkers with a ?-glucuronide cleavable unit, as well as intermediates thereof.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 16, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Yunyu Mao, Philip Moquist, Anusuya Choudhury, Wendel Doubleday
  • Publication number: 20200197524
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 25, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Christopher Scott Neumann, Kathleen Olivas, Robert Lyon, Kung-Pern Wang